The majority of people with diabetes live in low- and middle income countries1. Access to reliable and affordable supplies of insulin is a challenge for many. In fact, it is estimated that 50 million people lack access to insulin worldwide2.
Novo Nordisk has addressed this challenge since we introduced our Differential Pricing Policy for Least Developed Countries (LDCs) in 2001. Under this policy we offered human insulin in LDCs at a price that does not exceed 20% of the average realised price for Europe, the US, Canada and Japan.
Our continued commitment to having a low-cost insulin in our product portfolio and to producing and making human insulin available for years to come, is formulated in our Access to Insulin Commitment which was updated as of 2017.
In 2017, Novo Nordisk sold human insulin according to the Access to Insulin Commitment in 30 of the world’s 50 poorest countries. In total, 0.3 million patients were treated with insulins sold at or below the ceiling price. The average realised price for insulin sold under the programme was 3.0 USD/vial, corresponding to 0.12 USD per patient per day.
Beyond this scheme, Novo
Nordisk sold human insulin below the ceiling price in other
countries, reaching an estimated 5 million patients in 2017 compared
to an estimated 6.5 million patients in 2016. The number is affected
by wins or losses of tenders.
1. International Diabetes Federation. IDF Diabetes Atlas, 8th edition, 2017
2. ACCISS. Fact Sheet on Inequities and Inefficiencies in the global insulin market. Amsterdam: Health Action International; 2015. Retrieved from: http://haiweb.org/wp-content/uploads/2015/11/ACCISS-Fact-Sheet-1-Inequalities-in-Insulin-Market.pdf.Accessed September 2016